Injectable Antibodies: Products, Markets, Players and Forecasts

Introduction

Highlights

• Provides detailed analysis of injectable antibody market segments, market dynamics and market demographics
• Analyzes products, therapeutic demand drivers and evaluates commercial drug products in more than two dozen injectable antibodies
• Analyzes technologies and market development issues for injectable antibodies
• Provides market data and forecasts to 2016
• Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations

Greystone Research Associates is pleased to announce the publication of a new market study. Injectable Antibodies: Products, Markets, Players and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for therapeutic antibodies administered via injection. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

The Evolving Landscape for Therapeutic Antibodies

The administration of therapeutic antibodies via injection is becoming an increasingly important healthcare treatment method for a growing number diseases and indications having broad implications for patient health and well-being. The inherent instability of protein drugs has led to a number of challenges as the developers of injectable antibodies attempt to deal with packaging, handling, reconstitution and drug administration issues. These challenges are being compounded by the trend to patient self-medication, as population demographics and efforts by managed care providers to control healthcare costs drive the growth in drug self-administration, particularly for chronic conditions. This trend is introducing a new class of naive users to parenteral drug delivery. This report analyzes twenty-six injectable/Infusible therapeutic antibody drugs and examines key packaging, dosing, regulatory, economic and competitive factors that represent opportunities, risk factors and potential barriers to commercial success.

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Table of Contents

Executive Summary

Antibody Therapeutics Market Dynamics

• The Antibody Therapeutics Marketspace
• Clinical Trials and Drug Approvals
• The Competitive Landscape
• Demographics, Managed Care and Growth
• Risks and Opportunities

Formulating Antibody Drugs

• Formulation Strategies
• Antibody Formulation Technologies
• Antibody Packaging & Delivery
• Antibody Drug Distribution Strategies

Injectable Antibodies - Indications and Therapeutic Markets

• Asthma
• Infectious Disease
• Oncology
• Autoimmunity
• Osteoporosis
• Macular Degeneration

Injectable Antibody Drug Product Assessments and Forecasts

• Adalimumab (Humira)
• Alefacept (Amevive)
• Alemtuzumab (Campath)
• Belimumab (Benlysta)
• Bevacizumab (Avastin)
• Brentuximab vedotin (Adcetris)
• Canakinumab (Ilaris)
• Certolizumab (Cimzia)
• Cetuximab (Erbitux)
• Denosumab (Prolia)
• Eculizumab (Soliris)
• Gemtuzumab (Mylotarg)
• Golimumab (Simponi)
• Ibritumomab (Zevalin)
• Infliximab (Remicade)
• Natalizumab (Tysabri)
• Ofatumumab (Arzerra)
• Palivizumab (Synagis)
• Panitumumab (Vectibix)
• Omalizumab (Zolair)
• Ranibizumab (Lucentis)
• Rituximab (Rituxin)
• Tocilizumab (Actemra)
• Tositumomab (Bexxar)
• Trastuzumab (Herceptin)
• Ustekinumab (Stelara)

Market Factors

• Regulatory Issues
• Patient Compliance
• Healthcare Economics

Company Profiles

Injectable Antibodies: Products, Markets, Players and Forecasts published by Greystone Research Associates in May 17, 2012. This report price starts from US $ 3850.

Press Release

New Report Analyzes 26 Injectable and Infusible Therapeutic Antibody Drugs